Day: March 19, 2024

Announced positive randomized first-line HCC data showing superiority of TPST-1120 combination therapy across multiple study endpoints compared to standard of care Reported new biomarker data in two important subpopulations, PD-L1 negative and b-catenin mutant patients, consistent with MoA of TPST-1120 Preparing to move TPST-1120 into a pivotal Phase 3 trial in HCC and TPST-1495 into a Phase 2 in FAPBRISBANE, Calif., March 19, 2024 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the year ended 2023 and provided a corporate update. “2023 was a transformative year for Tempest. We announced strong positive randomized data showing the benefit of TPST-1120...

BELGRADE, Mont., March 19, 2024 (GLOBE NEWSWIRE) — Bridger Aerospace Group Holdings, Inc. (“Bridger”, “the Company” or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation’s largest aerial firefighting companies, today reported results for the fourth quarter and fiscal year ended December 31, 2023. The Company also reiterated its 2024 revenue and adjusted EBITDA guidance. Highlights:Record 2023 revenue of nearly $67 million despite slowest fire season in 20 years Record contract awards in 2023 including a 5-year $60 million exclusive use fire surveillance and technology contract in support of the Department of Interior First international deployment leads to the most territory covered in the history of the Company Joint Venture Partnership completed purchase of four Super Scoopers from the Spanish Government Established...

LIMASSOL, Cyprus, March 19, 2024 (GLOBE NEWSWIRE) — GDEV Inc. (NASDAQ: GDEV), an international gaming and entertainment company (“GDEV” or the “Company”) released its preliminary unaudited financial and operational results for the fourth quarter and full year ended December 31, 2023. Financial highlights: Fourth quarter 2023:Revenue of $109 million increased by 10% year-over-year. Bookings of $106 million increased by 4% year-over-year. Profit for the period of $11 million in Q4 2023 vs. loss of $77 million in Q4 2022. Adjusted EBITDA of $10 million in the fourth quarter 2023 compared to negative $9 million in the fourth quarter of 2022.Full year 2023:Revenue of $465 million declined by 3% year-over-year. Bookings of $422 million declined by 6% year-over-year. Profit for the period of $46 million in 2023 vs. $7 million in...

– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – – Oral Plogosertib Preclinical Data Support Precision Medicine Strategy in ARID1A- and SMARCA-Mutated Cancers – – Management to Host Conference Call at 4:30 pm ET Today – BERKELEY HEIGHTS, N.J., March 19, 2024 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced fourth quarter and full year 2023 financial results and provided a business update. “Following the recently announced precision medicine strategy for oral fadraciclib, our CDK2/9 inhibitor, we have determined the recommended Phase 2 dose (RP2D)...

Annual Revenue Grows 360% Year-Over-Year; Annual BTC Self-Mined Increases 550% to 3,407 Reports Realized Cost of Power of 3.2 Cents Per Kilowatt Hour in 2023, Outperforming Company Guidance of 3.5 Cents Per Kilowatt Hour by 9% Self-Mining Operating Capacity Reaches 8 EH/s, More Than Quadrupling Capacity Since Beginning of 2023 Reports Current Cash and Bitcoin Holdings of $49 million as of February 29, 2024 EASTON, Md., March 19, 2024 (GLOBE NEWSWIRE) — TeraWulf Inc. (Nasdaq: WULF) (“TeraWulf” or the “Company”), which owns and operates vertically integrated, domestic bitcoin mining facilities powered by more than 95% zero-carbon energy, today announced its financial results for the fourth quarter and full year ended December 31, 2023. Management Commentary “In addition to our outstanding financial achievements in 2023, attributable...

Figure 1Waterfall Plot for Patients in the 200 mg Dose Cohort of the Soquelitinib Phase 1/1b Clinical Trial for Peripheral T Cell Lymphoma. The plot shows the best percent change in tumor volume in the 21 evaluable patients (eligible patient population), as of January 22, 2024, that were measurable by CT scan or by Modified Severity-Weighted Assessment Tool (mSWAT) for patients with cutaneous involvement.Figure 2Swimmer Plot of Eligible Patient Population Demonstrating Response and Time on Therapy. Tumor histologies, as of January 22, 2024, are also shown indicating different types of T cell lymphoma. PTCL-NOS, peripheral T cell lymphoma not otherwise specified; CTCL, cutaneous T cell lymphoma of either Sezary or mycosis fungoides type; NKTCL, natural killer cell T cell lymphoma; ALCL, anaplastic large cell lymphoma; AITL,...

New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in 2025 IND Cleared for DT-168 for Treatment of Fuchs Endothelial Corneal Dystrophy (FECD) with Phase 1 Development to Start in 2024; Observational Study Underway to Confirm Patient Characteristics and Evaluate Potential Endpoints New Program Unveiled for Huntington’s Disease (HD) Targeting Reduction of Mutant Huntingtin with a GeneTAC™ Small Molecule Cash and Securities of $281.8 Million at Year-end 2023 Support Five-Year Operating Runway and Advancement of Up to Four Programs to Clinical Proof-of-Concept Conference Call and Webcast to be Held Today at 4:30pm ET CARLSBAD, Calif., March 19, 2024 (GLOBE NEWSWIRE) — Design Therapeutics,...